Xeris Biopharma officer reports tax share withholding

Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a Form 4 transaction where 29,300 shares of common stock were withheld by the company at $6.88 per share to cover income tax obligations on vested restricted stock units as of February 24, 2026.

Rhea-AI Filing Summary

Xeris Biopharma Holdings, Inc. officer Anh Tu Nguyen reported a Form 4 transaction where 29,300 shares of common stock were withheld by the company at $6.88 per share to cover income tax obligations on vested restricted stock units as of February 24, 2026.

After this tax-withholding disposition, Nguyen directly owned 395,023 shares of common stock, with additional indirect holdings of 3,710 shares through an IRA and 3,501 shares through children’s IRAs, for which he disclaims full beneficial ownership beyond his pecuniary interest.

Insider Trade Summary

Exercise Price or Tax Liability: 29,300 shares

Exercise Price or Tax Liability 3 txns

Insider Nguyen Anh Tu

Role See Remarks

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	29,300	$6.88	$202K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 395,023 shares (Direct); Common Stock — 3,710 shares (Indirect, By IRA); Common Stock — 3,501 shares (Indirect, By children's IRA)

Footnotes (2)

1. F1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of February 24, 2026.
2. F2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

FAQ

What insider transaction did XERS officer Anh Tu Nguyen report on this Form 4?

Anh Tu Nguyen reported a tax-withholding disposition of 29,300 Xeris Biopharma common shares. The company withheld these shares at $6.88 each to satisfy income tax obligations arising from vested restricted stock units on February 24, 2026.

Was the XERS Form 4 transaction an open-market sale of shares?

No, the Form 4 shows a tax-withholding disposition, not an open-market sale. Shares were withheld by Xeris Biopharma to cover income tax and withholding obligations tied to vested restricted stock units, coded as a tax-related transaction (code F).

How many Xeris Biopharma shares does Anh Tu Nguyen hold after this filing?

Following the tax-withholding transaction, Anh Tu Nguyen directly held 395,023 Xeris Biopharma common shares. The filing also reports 3,710 shares held indirectly through an IRA and 3,501 shares through children’s IRAs, subject to a beneficial ownership disclaimer.

What does transaction code F mean in the XERS Form 4 filing?

Transaction code F indicates shares used to pay an exercise price or tax liability. In this case, 29,300 Xeris Biopharma shares were withheld by the issuer to satisfy income tax and withholding obligations from the net settlement of vested restricted stock units.

How are the IRA and children’s IRA XERS shares treated in this Form 4?

The Form 4 lists 3,710 shares held indirectly via an IRA and 3,501 via children’s IRAs. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest, limiting how these holdings are attributed to him.

Does the XERS Form 4 indicate a change in Anh Tu Nguyen’s indirect ownership?

The filing reports indirect ownership levels after the transaction: 3,710 shares in an IRA and 3,501 in children’s IRAs. It characterizes these as indirect holdings and includes a disclaimer of beneficial ownership beyond his pecuniary interest in those accounts.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/25/2026 - 06:03 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Nguyen Anh Tu

(Last) (First) (Middle)

C/O XERIS BIOPHARMA HOLDINGS, INC.

1375 WEST FULTON STREET, SUITE 1300

(Street)

CHICAGO IL 60607

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Xeris Biopharma Holdings, Inc. [ XERS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		F		29,300(1)	D	$6.88	395,023	D
Common Stock								3,710(2)	I	By IRA
Common Stock								3,501(2)	I	By children's IRA

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares that have been withheld by the Issuer to satisfy its income tax and withholding and remittance obligations in connection with the net settlement of restricted stock units vested as of February 24, 2026.

2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Remarks:

Chief Medical Officer

	/s/ Beth Hecht, Attorney-in-Fact	02/25/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.